Masthead

Bone-Building Drug Zometa Disappoints in Breast Cancer Clinical Trial

| Comments (0)

Zometa.jpgMuch-anticipated and highly-disappointing results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. In an international trial of 3,360 women, the bone-building drug Zometa failed to prevent breast cancer recurrence and found no disease-free survival benefit among the majority of women with stage II/III disease.
 
Zometa did offer benefit to one subset of women: in those who were five years or more post-menopausal, there was a 29% improvement in overall survival.
 
Bisphosphonates' role in the treatment of breast cancer has been an active area of research focus, as previous clinical trials had shown that the class of drugs may have anti-cancer activity.
 
Sharon Giordano, M.D., associate professor in MD Anderson's Department of Breast Medical Oncology, was a commentator on today's press program where the findings were presented. In this video she shares her perspective.

Leave a comment

Search

Connect on social media

Sign In

Archives